Hyderabad-based drug discovery research and development company GVK Biosciences (GVK Bio) has entered into a drug discovery alliance with US-based Moulder Center for Drug Discovery Research at Temple University in Philadelphia.
As part of the multi-year collaboration, GVK Bio will be responsible for the target validation, lead identification and lead optimisation of small molecules in selected therapeutic areas, including cardiovascular, metabolic and central nervous system disorders, a release said.
The Moulder Center is stated to be used for both internal research within Temple University and for external collaborations with pharmaceutical and biotech companies and other universities.
“This collaboration with Temple University is among several academic collaborations GVK Bio has with leading research institutions,” GVK Bio’s CEO, Manni Kantipudi, said.
Moulder Center director Magid Abou-Gharbia said the business model reflected the increasing trend of collaborations between academic centres of excellence and pharmaceutical companies to discover new drugs.
